In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes.

Mayne KJ.; Herrington WG.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes.

Mayne KJ., Herrington WG.

Source citationAgarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84. 35023547.

Original publication

DOI

10.7326/j22-0029

Type

Journal article

Journal

Annals of internal medicine

Publication Date

03/05/2022

Volume

175

Addresses

University of Oxford, Oxford, Oxfordshire, England, UK (K.J.M., W.G.H.).

Keywords

Kidney, Humans, Diabetes Mellitus, Type 2, Naphthyridines, Renal Insufficiency, Chronic